Genetic and Monogenic Causes of Extrahepatic Portal Venous Obstruction
Inherited thrombophilias are the primary genetic causes of extrahepatic portal vein obstruction (EHPVO), with protein C and S deficiencies, factor V Leiden mutation, prothrombin G20210A mutation, and SMAD4 gene mutations (in JP-HHT overlap syndrome) representing the key monogenic etiologies.
Primary Inherited Thrombophilias
The most clinically significant genetic causes include:
Protein C and S deficiencies: Combined deficiency has been documented as a direct cause of EHPVO, particularly in young patients without traditional risk factors 1. These anticoagulant protein deficiencies create a hypercoagulable state predisposing to portal vein thrombosis.
Factor V Leiden mutation: Shows stronger association with Budd-Chiari syndrome than isolated PVT, but remains a relevant genetic risk factor for portal venous thrombosis 2.
Prothrombin G20210A mutation: Demonstrates stronger association with PVT compared to Budd-Chiari syndrome, making it particularly relevant for EHPVO 2.
Rare Monogenic Syndromes
SMAD4 gene mutations cause juvenile polyposis-hereditary hemorrhagic telangiectasia (JP-HHT) overlap syndrome, which paradoxically presents with both bleeding manifestations and thrombotic complications including EHPVO 3. This autosomal dominant disorder demonstrates that HHT, typically considered a bleeding disorder, carries increased vascular thrombosis risk.
Multifactorial Genetic Interactions
A critical caveat: EHPVO development typically requires multiple risk factors—a genetically determined thrombophilic state plus a second hit such as infection, abdominal surgery, or local inflammatory processes 2, 4. Isolated genetic mutations alone are often insufficient.
The geographic and age-related variation is important: while inherited thrombophilias are well-documented in adults with EHPVO, studies in children have shown that hereditary or acquired coagulation disorders do NOT play a significant role in pediatric EHPVO pathogenesis 5. This suggests different etiologic mechanisms between age groups.
Clinical Approach to Genetic Evaluation
When to suspect genetic causes:
- Young patients (<40 years) presenting with EHPVO
- Absence of traditional risk factors (cirrhosis, malignancy, infection, surgery)
- Family history of thrombosis
- Recurrent thrombotic events
Recommended thrombophilia workup should include 2:
- Protein C and S levels
- Factor V Leiden mutation
- Prothrombin G20210A mutation
- Antiphospholipid antibodies
- Myeloproliferative disorder screening (JAK2 mutation)
- Consider SMAD4 genetic testing if clinical features suggest HHT (epistaxis, telangiectasias, AVMs)
The AASLD guidance emphasizes that thrombophilia testing recommendations should guide evaluation of risk factors for venous thrombosis in portal systems 6, though specific genetic testing algorithms are not explicitly detailed in current guidelines.